These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22768888)

  • 1. Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.
    Thomas A; Heinemann L
    J Diabetes Sci Technol; 2012 May; 6(3):572-80. PubMed ID: 22768888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.
    Thomas A; Schönauer M; Achermann F; Schnell O; Hanefeld M; Ziegelasch HJ; Mastrototaro J; Heinemann L
    Diabetes Technol Ther; 2009 Jun; 11(6):399-409. PubMed ID: 19459770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Composite Glycemic Indices: A Comparison of the Comprehensive Glucose Pentagon Across Diabetes Types and HbA1c Levels.
    Rama Chandran S; A Vigersky R; Thomas A; Lim LL; Ratnasingam J; Tan A; S L Gardner D
    Diabetes Technol Ther; 2020 Feb; 22(2):103-111. PubMed ID: 31502876
    [No Abstract]   [Full Text] [Related]  

  • 4. Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes.
    Wakasugi S; Mita T; Katakami N; Okada Y; Yoshii H; Osonoi T; Kuribayashi N; Taneda Y; Kojima Y; Gosho M; Shimomura I; Watada H
    Cardiovasc Diabetol; 2021 Jan; 20(1):15. PubMed ID: 33413339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of glucose management indicator for the estimation of glucose disposal rate in people with type 1 diabetes.
    Cutruzzolà A; Parise M; Scavelli FB; Fiorentino R; Lucà S; Di Molfetta S; Gnasso A; Irace C
    Nutr Metab Cardiovasc Dis; 2024 Oct; 34(10):2344-2352. PubMed ID: 39069471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control.
    Šoupal J; Škrha J; Fajmon M; Horová E; Mráz M; Škrha J; Prázný M
    Diabetes Technol Ther; 2014 Apr; 16(4):198-203. PubMed ID: 24401008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Cosentino C; Monami M; Mannucci E; Pala L
    Acta Diabetol; 2021 Apr; 58(4):401-410. PubMed ID: 32789691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment recommendations following 3-day masked continuous glucose monitoring (CGM) in youth with type 1 diabetes.
    Rasbach LE; Atkins AE; Milaszewski KM; Keady J; Schmidt LM; Volkening LK; Laffel LM
    J Diabetes Sci Technol; 2014 May; 8(3):494-7. PubMed ID: 24876612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset-Applications to the pediatric diabetes population.
    Forlenza GP; Pyle LL; Maahs DM; Dunn TC
    Pediatr Diabetes; 2017 Nov; 18(7):622-628. PubMed ID: 27878929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phenomenon of HbA1c stability and the risk of hypoglycemia in long-standing type 1 diabetes.
    Wolnik B; Orłowska-Kunikowska E; Błaszkowska M; Graff B; Wolf J; Czupryniak L; Narkiewicz K
    Diabetes Res Clin Pract; 2019 Jun; 152():96-102. PubMed ID: 31108139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.
    Jin SM; Kim TH; Bae JC; Hur KY; Lee MS; Lee MK; Kim JH
    Diabetes Res Clin Pract; 2014 May; 104(2):266-72. PubMed ID: 24630619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: Determination of optimal sampling duration.
    Piona C; Marigliano M; Mozzillo E; Franzese A; Zanfardino A; Iafusco D; Maltoni G; Zucchini S; Delvecchio M; Maffeis C
    Pediatr Diabetes; 2020 Dec; 21(8):1485-1492. PubMed ID: 32935887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship Between CGM-Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With Type 1 Diabetes.
    Toschi E; Slyne C; Sifre K; O'Donnell R; Greenberg J; Atakov-Castillo A; Carl S; Munshi M
    Diabetes Care; 2020 Oct; 43(10):2349-2354. PubMed ID: 32461211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring.
    Beck R; Steffes M; Xing D; Ruedy K; Mauras N; Wilson DM; Kollman C;
    Pediatr Diabetes; 2011 Dec; 12(8):690-5. PubMed ID: 21496193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the inter-subject variability in the relationship between glucose monitoring metrics and glycated hemoglobin for pediatric patients with type 1 diabetes.
    Bosoni P; Calcaterra V; Tibollo V; Malovini A; Zuccotti G; Mameli C; Sacchi L; Bellazzi R; Larizza C
    J Pediatr Endocrinol Metab; 2021 May; 34(5):619-625. PubMed ID: 33823102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships among different glycemic variability indices obtained by continuous glucose monitoring.
    Saisho Y; Tanaka C; Tanaka K; Roberts R; Abe T; Tanaka M; Meguro S; Irie J; Kawai T; Itoh H
    Prim Care Diabetes; 2015 Aug; 9(4):290-6. PubMed ID: 25456706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.
    Matsutani D; Sakamoto M; Iuchi H; Minato S; Suzuki H; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
    Cardiovasc Diabetol; 2018 Mar; 17(1):36. PubMed ID: 29514695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes.
    Maahs DM; Chase HP; Westfall E; Slover R; Huang S; Shin JJ; Kaufman FR; Pyle L; Snell-Bergeon JK
    Diabetes Technol Ther; 2014 May; 16(5):284-91. PubMed ID: 24450776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.